Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
about
GenoType® MTBDRsl assay for resistance to second-line anti-tuberculosis drugsUse of GeneXpert Remnants for Drug Resistance Profiling and Molecular Epidemiology of Tuberculosis in Libreville, Gabon.QSAR based therapeutic management of M. tuberculosis.Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and MoxifloxacinRole of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical IsolatesPopulation-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs.Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.Limited Effect of Later-generation Fluoroquinolones in the Treatment of Ofloxacin-resistant and Moxifloxacin-susceptible Multidrug-resistant Tuberculosis.Evolution of Phenotypic and Molecular Drug Susceptibility Testing.Emerging drugs and drug targets against tuberculosis.Pathogen-based precision medicine for drug-resistant tuberculosis
P2860
Q28068545-669D0462-8658-4F39-BCDB-0E83A2450E07Q33832822-02596F63-1D97-4EBB-97B8-E9D4B87EDD38Q36359056-B28058CD-CD8F-43A3-86B0-6886BE6A6C80Q36794791-830924BE-87AA-465F-893E-D828C959AD05Q37203747-D00B4E63-4D2F-4416-9683-2112A1625CADQ37203798-26C19F1B-67E5-47C3-97E3-2A627870AAE7Q37270722-95CB8E8D-CBD1-48A9-AA30-DDF1FB18A31AQ38739933-93031BA3-6EBB-4CD0-A973-CABB662D0FBEQ38839490-C0620A4A-8862-4D44-9D95-35D176BA0C47Q38848119-E505B42D-665F-46A9-98F7-CF51609F8387Q39456569-65B2B832-B8F8-4B07-99FC-FA11CF3C1D23Q40043590-253F36CB-2F10-4E3A-A7F0-0CBA6D198FAEQ40202149-FBF58AA9-3D4D-4550-8DFE-2F1B5EE1A213Q41987738-DFEDB95F-C72A-4B54-9801-ADC2FED7A8EBQ47237569-910F5598-B04D-489A-AD3E-DA80A2D423D0Q47371137-79BBB5B1-10AC-4D17-906C-E698FC5B6E55Q47632774-E1F4D8C6-7D84-4F15-BCF9-9A5930A872ADQ53746587-9A2B2540-66A7-462C-929C-862DF962A55EQ58602447-A6EA806E-15BF-4D80-B306-67B1D93A9391
P2860
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
@en
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
@nl
type
label
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
@en
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
@nl
prefLabel
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
@en
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
@nl
P2093
P2860
P356
P1476
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.
@en
P2093
A Van Deun
C J Meehan
H L Rieder
K Fissette
K J M Aung
M A Hossain
M Gumusboga
W B de Rijk
P2860
P304
P356
10.1093/JAC/DKV360
P407
P577
2015-11-24T00:00:00Z